Viveve Medical (VIVE) Stock Price

Viveve Medical Price

NASDAQ·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue at Viveve Medical has contracted by 1.7% per year over the past 19 years to 6.43 M USD. Viveve Medical's net margin stands at -342.8%, down from -239.6% several years earlier. Analysts set a median price target of 4.77 USD, implying 2,384,150.1% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 700% above its 52-week low.

Viveve Medical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Viveve Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Viveve Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Viveve Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Viveve Medical Stock Price History
DateViveve Medical Price
8/14/20260.00 USD
8/13/20260.00 USD
8/12/20260.00 USD
8/11/20260.00 USD
8/10/20260.00 USD
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/3/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/3/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/16/20260.00 USD
3/9/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/17/20250.00 USD
12/10/20250.00 USD
12/5/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/25/20250.00 USD
11/17/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/21/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
9/25/20250.00 USD
9/19/20250.00 USD
9/17/20250.00 USD
9/4/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/25/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Viveve Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
6.57 M USD
-31.86 M USD
-42.53 M USD
Jan 1, 2020
5.48 M USD
-20.62 M USD
-21.92 M USD
Jan 1, 2021
6.43 M USD
-20.77 M USD
-22.03 M USD
Jan 1, 2022 (e)
0.00 USD
-20.93 M USD
0.00 USD
Jan 1, 2023 (e)
0.00 USD
-20.53 M USD
0.00 USD
Jan 1, 2024 (e)
22.33 M USD
-14.32 M USD
-9.98 M USD
Jan 1, 2025 (e)
39.58 M USD
-39.58 M USD
-1.21 M USD
Jan 1, 2026 (e)
45.22 M USD
-20.89 M USD
-18.72 M USD

Viveve Medical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 20, 2026, 3:09 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
–1.001.00–1.007.0015.0018.006.005.006.00––22.0039.0045.00
–––––600.00114.2920.00-66.67-16.6720.00–––77.2715.38
–100.00100.00–100.0028.5746.6738.8916.6720.0016.67––16.6716.6716.67
1.001.001.001.001.002.007.007.001.001.001.001.001.003.676.507.50
-3.00-4.00-4.00-5.00-11.00-18.00-33.00-44.00-31.00-20.00-20.00-20.00-20.00-14.00-39.00-20.00
–-400.00-400.00–-1,100.00-257.14-220.00-244.44-516.67-400.00-333.33––-63.64-100.00-44.44
-5.00-8.003.00-6.00-12.00-20.00-36.00-49.00-42.00-21.00-22.00––-9.00-1.00-18.00
–60.00-137.50-300.00100.0066.6780.0036.11-14.29-50.004.76–––-88.891,700.00
10.0910.09––0.010.010.020.040.712.1710.0910.0910.0910.0910.0910.09
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Viveve Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Viveve Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Viveve Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Viveve Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Viveve Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Viveve Medical stock margins

The Viveve Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Viveve Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Viveve Medical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
48.69 %
-221.02 %
-239.60 %
Jan 1, 2018
39.53 %
-242.83 %
-265.60 %
Jan 1, 2019
15.47 %
-485.17 %
-647.57 %
Jan 1, 2020
5.40 %
-376.38 %
-399.98 %
Jan 1, 2021
9.65 %
-323.23 %
-342.78 %
Jan 1, 2022 (e)
9.65 %
- %
0.00 %
Jan 1, 2023 (e)
9.65 %
- %
0.00 %
Jan 1, 2024 (e)
9.65 %
-64.14 %
-44.71 %

Viveve Medical Stock Revenue, EBIT, Earnings per Share

The Viveve Medical earnings per share therefore indicates how much revenue Viveve Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
788.04 USD
-1,741.75 USD
-1,888.14 USD
Jan 1, 2018
521.61 USD
-1,266.62 USD
-1,385.41 USD
Jan 1, 2019
9.28 USD
-45.03 USD
-60.10 USD
Jan 1, 2020
2.53 USD
-9.50 USD
-10.10 USD
Jan 1, 2021
0.64 USD
-2.06 USD
-2.18 USD
Jan 1, 2022 (e)
0.00 USD
-2.07 USD
0.00 USD
Jan 1, 2023 (e)
0.00 USD
-2.04 USD
0.00 USD
Jan 1, 2024 (e)
2.21 USD
-1.42 USD
-0.99 USD

Viveve Medical business model & stock analysis

Viveve Medical Inc. is a company specializing in the development of medical technology. The company is based in Englewood, Colorado, USA, and has been listed on the NASDAQ exchange since 2005. Viveve was founded to meet the needs of women in improving their physical health. The company has developed an innovative technology that allows women to maintain their vaginal health. History of Viveve Medical Inc. Viveve Medical Inc. was founded by an experienced team of physicians and engineers. The company was launched by Dr. William Doyle and a group of experts with extensive experience in the field of medical technology. Dr. Doyle brought his experience in developing technologies to improve skin structure and firmness to the company. The technical expertise of the other team members helped in the development of devices that can improve women's vaginal health. Business model of Viveve Medical Inc. Viveve Medical Inc. is an innovative company that aims to improve women's vaginal health. Viveve's products are based on the patented radiofrequency technology developed by the company. The technology is used in a device called the Viveve System, which is used by medical professionals to help women of different ages in the treatment of pelvic disorders and problems. The company has marketed its products in over 50 countries worldwide. It also collaborates with local distributors and other medical device manufacturers to promote and sell its products on the market. Viveve Medical Inc. offers innovative technologies such as the Viveve System, which allow women to improve their vaginal health and enhance their well-being. The company has various divisions, including medical technology, pharmacy, and medical services. Each division has a different mission and offers different products and services. Products of Viveve Medical Inc. Viveve Medical Inc. has launched several products that aim to improve women's vaginal health. The company's main product is the Viveve System, a device used in the treatment of pelvic disorders and problems. The device utilizes Viveve's patented radiofrequency technology to increase collagen production in tissue. This allows the Viveve System to combat vaginal laxity and incontinence. The Viveve System should always be used by trained medical professionals. In addition to the Viveve System, the company offers other products to improve women's physical health. This includes hormonal therapies that help with hormonal system disorders and alleviate vaginal dryness and pain, as well as surgical interventions for the treatment of irregularities in the female reproductive system. In the pharmaceutical division, the company has effective medications such as kisspeptin in the developmental stage, prescribed for increasing libido in women. Conclusion Overall, Viveve Medical Inc. is a company dedicated to improving women's vaginal health. The company has the innovative technology of the Viveve System and also offers a variety of products and services to enhance women's well-being. Viveve Medical Inc. is a key player in the field of medical technology, providing solutions for a variety of issues.

Viveve Medical SWOT Analysis

Strengths

Viveve Medical Inc possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company offers a unique and innovative medical technology known as the Viveve System that addresses various conditions affecting women's health. This proprietary system sets Viveve apart from its competitors and allows it to target a niche market segment. Additionally, the company has an experienced research and development team, enabling it to continually enhance its product offerings and stay ahead in the rapidly evolving healthcare industry.

Furthermore, Viveve Medical Inc has established strong partnerships and collaboration with healthcare providers, securing extensive distribution networks and expanding its market reach. These partnerships not only help in promoting the company's products but also provide valuable insights and feedback for product improvement.

Weaknesses

Despite its strengths, Viveve Medical Inc also faces certain weaknesses that need to be addressed. Firstly, as a relatively small company, it may lack the financial resources and brand recognition compared to larger competitors. This could potentially limit its marketing efforts and hinder market penetration.

Moreover, Viveve's product portfolio is currently focused on women's health, which may restrict its target market to a niche segment. Diversification into other healthcare areas could be considered to mitigate this weakness and increase revenue streams.

Opportunities

The evolving healthcare industry presents several opportunities for Viveve Medical Inc. One such opportunity lies in the growing demand for innovative medical technologies and treatments for women's health issues. With its Viveve System, the company is well-positioned to capitalize on this trend and gain a significant market share.

Furthermore, partnerships and collaborations with major pharmaceutical companies or healthcare institutions can open doors to broader distribution channels and increased market exposure. The company could also explore expanding its product offerings to cater to a wider range of healthcare needs, tapping into additional market segments.

Threats

Viveve Medical Inc faces certain threats that could potentially impact its business operations and market position. The competitive landscape is a significant threat, as larger and more established companies with greater resources may enter the women's health market or develop competing technologies. This could lead to increased competition and potential loss of market share for Viveve.

Additionally, regulatory and compliance requirements in the healthcare industry pose ongoing threats. Changes in regulations or delays in obtaining necessary approvals may hinder the company's ability to launch and market new products in a timely manner.

Viveve Medical Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Viveve Medical Employees
Details
Date
Viveve Medical Employees
Jan 1, 2014
- Employees
Jan 1, 2015
- Employees
Jan 1, 2016
- Employees
Jan 1, 2017
- Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees

Viveve Medical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Viveve Medical historical P/E ratio, EBIT multiple, and P/S ratio

Viveve Medical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Viveve Medical shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
19,400.00 Stocks
Jan 1, 2018
35,500.00 Stocks
Jan 1, 2019
707,600.00 Stocks
Jan 1, 2020
2.17 M Stocks
Jan 1, 2021
10.09 M Stocks
Jan 1, 2022 (e)
10.09 M Stocks
Jan 1, 2023 (e)
10.09 M Stocks
Jan 1, 2024 (e)
10.09 M Stocks

Viveve Medical stock splits

In Viveve Medical's history, there have been no stock splits.

Current Viveve Medical forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
4.77
Last Price
0.00
Currency
USD
12M Return Potential
2,384,150.06 %
LTM Return
0 %

Viveve Medical Analyst Rating Actions

DateFirmActionRatingReliability
11/25/2020
Stifel Nicolaus
Stifel Nicolaus
DowngradeBuyHold59
11/25/2020
Raymond James
Raymond James
MaintainedOutperform64
11/25/2020
Mizuho Securities
Mizuho Securities
DowngradeBuyUnderperform31
11/25/2020
Mizuho
Mizuho
DowngradeBuyUnderperform31
11/25/2020
Maxim Group
Maxim Group
DowngradeBuyHold–
11/25/2020
Ladenburg Thalmann
Ladenburg Thalmann
UpgradeNeutralBuy66
12/3/2019
Ladenburg Thalmann
Ladenburg Thalmann
UpgradeNeutralBuy66
7/24/2019
Ladenburg Thalmann
Ladenburg Thalmann
DowngradeBuyNeutral66
7/23/2019
Stifel Nicolaus
Stifel Nicolaus
DowngradeBuyHold59
7/23/2019
Raymond James
Raymond James
DowngradeOutperformMarket Perform64

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Viveve Medical Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
11/8/2023-0.38USD-2.99 MUSD-2023 Q3
8/9/2023-0.54USD-2.54 MUSD-2023 Q2
11/10/2022-0.67USD-1.73 MUSD-2022 Q3

Viveve Medical shareholder structure

% Name
0.00000%
Old Point Trust & Financial Services N.A.
Old Point Trust & Financial Services N.A.

Viveve Medical Beneficial Ownership Filings (SEC 13D/G)

Free Float
100.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
67.20%
Nathan D. Hukill
Nathan D. Hukill
SEC ↗
67.20%
CR Group L.P.
CR Group L.P.
SEC ↗
65.62%
Itaú Unibanco Holding S.A.
Itaú Unibanco Holding S.A.
SEC ↗
21.10%
Brigitte Smith
Brigitte Smith
SEC ↗
20.00%
GBS Venture Partners Limited
GBS Venture Partners Limited
SEC ↗
20.00%
GBS BioVentures III
GBS BioVentures III
SEC ↗
14.20%
Wilmot B. Harkey
Wilmot B. Harkey
SEC ↗
14.20%
Dan Mack
Dan Mack
SEC ↗
14.20%
Daniel Mack
Daniel Mack
SEC ↗
11.00%
Scudder Kemper Investments, Inc.
Scudder Kemper Investments, Inc.
SEC ↗

Viveve Medical Executives and Management Board

6 members · avg. age 57 · 50 % women

SD

Mr. Scott Durbin (53)

Chief Executive Officer, Director · since 2013

2.68 M USD

Management

JR

Mr. Jim Robbins (58)

Senior Vice President - Finance and Administration

701,049.00 USD

Board of Directors

SB

Mr. Steven Basta (55)

Independent Chairman of the Board

469,443.00 USD
AM

Ms. Arlene Morris

Independent Director

232,630.00 USD
DJ

Ms. Deborah Jorn (64)

Independent Director

208,880.00 USD
SP

Dr. Sharon Presnell (53)

Independent Director

196,125.00 USD

Viveve Medical Supply Chain

Viveve Medical Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Excelsior Medical
Customer·Health Care Providers & Services·TW
0.46
0.62
0.18
-0.51
-0.62
-0.35
2
Merck & Co
Supplier·Pharmaceuticals·US
-0.53
-0.48
-0.33
-0.59
-0.42
-0.31

Frequently asked questions about Viveve Medical

Viveve Medical Inc is a medical technology company specializing in women's health. Its business model revolves around developing and commercializing innovative solutions to address various medical conditions affecting women. The company's flagship product, Viveve System, utilizes cryogen-cooled monopolar radiofrequency (CMRF) technology to provide non-invasive treatment for vaginal laxity. This cutting-edge technology stimulates collagen production and tightens the vaginal tissue, ultimately enhancing sexual function and improving overall quality of life for women. Viveve Medical Inc aims to improve women's health outcomes by offering clinically proven and safe solutions for conditions that often go untreated or undiagnosed.

Viveve Medical Inc primarily operates in the healthcare industry.

The main competitors of Viveve Medical Inc in the market are BTL Industries, InMode Ltd, and Lumenis Ltd. These companies also operate in the medical aesthetics industry and offer products and services similar to Viveve Medical Inc. BTL Industries specializes in non-invasive body shaping and tightening, while InMode Ltd is known for its innovative radiofrequency-based aesthetic solutions. Lumenis Ltd is a global leader in energy-based medical solutions, including those for women's health issues. The competition among these companies drives innovation and enhances options for customers seeking medical treatment in the aesthetic field.

Viveve Medical Inc is a renowned medical technology company that specializes in women's health solutions. Founded in 2005, the company has emerged as a pioneering force in offering non-invasive treatments for common feminine health concerns. Viveve Medical is known for its patented Viveve System, which utilizes radiofrequency energy to stimulate collagen production and improve tissue restoration. With a commitment to innovation and clinical research, the company aims to enhance the lives of women worldwide. Viveve Medical Inc continues to evolve and expand its portfolio of advanced solutions for a range of medical conditions related to women's health.

Viveve Medical Inc, a leading medical technology company, has achieved several significant milestones. As of now, the company has successfully developed and commercialized its innovative Viveve System. This non-invasive treatment option offers effective vaginal tissue restoration and rejuvenation, addressing conditions such as vaginal laxity. Viveve Medical has also expanded its global presence by obtaining regulatory approvals and launching its products in various countries, including the United States, Canada, and Europe. Moreover, Viveve Medical Inc has made advancements in clinical research, demonstrating the safety and efficacy of its products in multiple studies. These achievements have strengthened Viveve Medical's position as a trusted provider of innovative women's health solutions.

Viveve Medical Inc is primarily present in various countries and regions across the globe. The company has a global presence with a focus on North America, Europe, Asia, and the Middle East. Viveve Medical Inc has established its operations and market reach in countries like the United States, Canada, Germany, France, the United Kingdom, China, Japan, Australia, and the United Arab Emirates. With its strategic expansion plans, Viveve Medical Inc continues to strengthen its market presence and deliver innovative medical solutions in these key regions, providing its products and services to healthcare professionals and patients worldwide.

Viveve Medical Inc is a leading medical technology company focused on women's health. The company's core values include innovation, quality, and patient-centricity. Through their innovative solutions, Viveve aims to improve the lives of women by addressing various health conditions. Their corporate philosophy emphasizes a commitment to scientific rigor, evidence-based practices, and delivering safe and effective treatments. Viveve Medical Inc prioritizes providing exceptional patient care and improving quality of life through their advanced medical devices. With a strong focus on research and development, the company continues to develop and market innovative solutions to meet the evolving needs of women worldwide.

Analysts currently set an average price target of 4.77 USD for the Viveve Medical stock (median: 4.77 USD), implying +2.4 M % versus the latest price. The consensus is based on 8 analyst ratings.

Viveve Medical Analyst Price Targets 2026

8 analysts currently rate the Viveve Medical stock: 7 recommend buying, 1 holding and 0 selling.

Viveve Medical Analyst Price Targets 2026

Converted at the current exchange rate, the Viveve Medical share trades at 0.00 EUR (0.00 USD).

The Viveve Medical share (VIVE) is listed on 1 stock exchanges, including: NASDAQ (VIVE).

Viveve Medical Inc. is an innovative and advanced company in the field of medical technology, specializing in the development and marketing of devices and products for the treatment of sexual dysfunction, incontinence, and other women-specific health problems. The main product of Viveve Medical Inc. is the Viveve System, a non-invasive method for strengthening and tightening vaginal tissue through collagen stimulation. The Viveve System uses targeted radiofrequency energy to stimulate collagen production and firm the vaginal tissue, resulting in improved sexual function, better bladder control, and reduced risk of vaginal dryness. Additionally, Viveve Medical Inc. offers a range of products to improve female health and well-being, including feminine hygiene products, treatments for menstrual discomfort and post-menopausal symptoms, and contraceptive products. The business activities of Viveve Medical Inc. are conducted in three main segments: Cardiovascular/International Markets, US Business, and OEM (Original Equipment Manufacturer). In the Cardiovascular/International Markets segment, the company's activities are focused on marketing its products and services in international markets, as well as developing product and service offerings for cardiovascular diseases. The US Business segment focuses on marketing the Viveve System in the American market and developing new products for marketing in the US. In this segment, Viveve offers a range of services to ensure product quality, reliability, and safety. The OEM segment deals with the development and provision of solutions for custom product needs and requirements of international partners and customers. The company offers customized products and services to meet the needs of its customers. Overall, Viveve Medical Inc.'s business model is focused on providing innovative and high-quality products and services in the field of female health and well-being. By diversifying its activities in various business areas and focusing on the development and marketing of new products and services, Viveve Medical Inc. is well positioned to further expand its leading position in the medical technology industry.

The revenue cannot currently be calculated for Viveve Medical.

The profit cannot currently be calculated for Viveve Medical.

The P/E ratio cannot be calculated for Viveve Medical at the moment.

The P/S cannot be calculated for Viveve Medical currently.

The Eulerpool Quality Score for Viveve Medical is 3/10.

The ISIN of Viveve Medical is US92852W5013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Viveve Medical is A2QJQB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Viveve Medical is VIVE. The ticker symbol is used to trade Viveve Medical shares on the stock exchange.

Viveve Medical paid dividends every year for the past 0 years.

Viveve Medical is assigned to the 'Health' sector.

The dividends of Viveve Medical are distributed in USD.

All fundamentals and in-depth analysis of Viveve Medical

Our stock analysis for Viveve Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Viveve Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Viveve Medical Stock
Viveve Medical Revenue→
Viveve Medical Stock
Viveve Medical Net Income→
Viveve Medical Stock
Viveve Medical P/E→
Viveve Medical Stock
Viveve Medical P/S→
Viveve Medical Stock
Viveve Medical EBIT→
Viveve Medical Stock
Viveve Medical Dividend→
Viveve Medical Stock
Viveve Medical Directors Dealings→
Viveve Medical Stock
Viveve Medical Stocks→
Viveve Medical Stock
Viveve Medical Market capitalization→
Viveve Medical Stock
Viveve Medical Debt→
Viveve Medical Stock
Viveve Medical Liabilities→
Viveve Medical Stock
Viveve Medical Equity→
Viveve Medical Stock
Viveve Medical AAQS→
Viveve Medical Stock
Viveve Medical Employees→
Viveve Medical Stock
Viveve Medical ROE→
Viveve Medical Stock
Viveve Medical ROA→
Viveve Medical Stock
Viveve Medical ROCE→
Viveve Medical Stock
Viveve Medical News→
Viveve Medical Stock
Viveve Medical Analyst Price Targets→

Health Stocks

Vivoryon TherapeuticsVivestoVivosVivani MedicalVivos TherapeuticsVIVA Biotech HoldingsVivoSim LabsVitura HealthViyash ScientificVitrolifeVizionfocusVitasora HealthAll Stocks A–Z →